September 17, 2025

Effectiveness of Cyclophosphamide and Immunosuppressants in Systemic Sclerosis-associated Interstitial Lung Disease: A Meta-analysis.

View Full Paper

Ask AI

Bookmark

Cyclophosphamide showed potential benefits for dyspnea but was less favored for lung function compared to azathioprine.
Meta-analysis indicated azathioprine was superior to cyclophosphamide for forced vital capacity and lung diffusion capacity.
CYC was beneficial over placebo for improving dyspnea scores, which suggests it may help alleviate symptoms.
Ongoing research is necessary to determine the safety and efficacy of CYC and optimize treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This meta-analysis compares cyclophosphamide and other immunosuppressants in systemic sclerosis-associated lung disease, revealing insights on treatment efficacy.

Cite This Study

Anwar et al. (2025) studied this question.

synapsesocial.com/papers/68d43294713b0b5dfea71f92 https://doi.org/10.59556/japi.73.1124

View Full Paper

Ask AI

Bookmark

Implication

This meta-analysis compares cyclophosphamide and other immunosuppressants in systemic sclerosis-associated lung disease, revealing insights on treatment efficacy.

Effectiveness of Cyclophosphamide and Immunosuppressants in Systemic Sclerosis-associated Interstitial Lung Disease: A Meta-analysis.

Key Points

Discussion

Implication

Cite This Study

Effectiveness of Cyclophosphamide and Immunosuppressants in Systemic Sclerosis-associated Interstitial Lung Disease: A Meta-analysis.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider